Oncology Reviews (Sep 2011)
Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time
Abstract
Despite being the very first molecular targeted agents registered for the treatment of advanced kidney cancer (in the post-cytokines setting), Sorafenib seemed to lose its momentum as a credible first-line treatment option, when it proved not to be superior to Interferon within a randomized phase II trial...
